IDEXX Laboratories, Inc. $IDXX Shares Sold by TD Asset Management Inc

Posted by Brenda Bartman on Jun 5th, 2026

TD Asset Management Inc reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 11.9% during the 4th quarter, Holdings Channel reports. The fund owned 267,850 shares of the company’s stock after selling 36,340 shares during the quarter. TD Asset Management Inc’s holdings in IDEXX Laboratories were worth $181,209,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Virtus Advisers LLC acquired a new stake in IDEXX Laboratories in the third quarter valued at $26,000. Park Place Capital Corp acquired a new stake in IDEXX Laboratories in the fourth quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 20 shares in the last quarter. Wormser Freres Gestion raised its stake in IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after buying an additional 47 shares in the last quarter. Finally, WealthCollab LLC acquired a new stake in IDEXX Laboratories in the second quarter valued at $30,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on IDXX shares. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, Stifel Nicolaus cut their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $751.00.

Check Out Our Latest Stock Analysis on IDXX

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $564.74 on Friday. The stock’s 50-day moving average is $563.32 and its two-hundred day moving average is $632.63. The firm has a market cap of $44.55 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $506.91 and a 1 year high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.